AP200603810A0 - 4-Phenylamino-quinazolin-6-yl-amides - Google Patents

4-Phenylamino-quinazolin-6-yl-amides

Info

Publication number
AP200603810A0
AP200603810A0 AP200603810A AP200603810A AP200603810A0 AP 200603810 A0 AP200603810 A0 AP 200603810A0 AP 200603810 A AP200603810 A AP 200603810A AP 200603810 A AP200603810 A AP 200603810A AP 200603810 A0 AP200603810 A0 AP 200603810A0
Authority
AP
ARIPO
Prior art keywords
quinazolin
phenylamino
amides
yl
Prior art date
Application number
AP200603810A
Other versions
AP2204A (en
Inventor
Stephen Alan Fakhoury
Helen Tsenwhei Lee
Jessica Elizabeth Reed
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US56887204P priority Critical
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to PCT/IB2005/001139 priority patent/WO2005107758A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP200603810(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AP200603810A0 publication Critical patent/AP200603810A0/en
Application granted granted Critical
Publication of AP2204A publication Critical patent/AP2204A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AP200603810A 2004-05-06 2005-04-25 4-phenylamino-quinazolin-6-yl-amides. AP2204A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US56887204P true 2004-05-06 2004-05-06
PCT/IB2005/001139 WO2005107758A1 (en) 2004-05-06 2005-04-25 4-phenylamino-quinazolin-6-yl-amides

Publications (2)

Publication Number Publication Date
AP200603810A0 true AP200603810A0 (en) 2006-12-31
AP2204A AP2204A (en) 2011-02-07

Family

ID=34965519

Family Applications (1)

Application Number Title Priority Date Filing Date
AP200603810A AP2204A (en) 2004-05-06 2005-04-25 4-phenylamino-quinazolin-6-yl-amides.

Country Status (45)

Country Link
US (3) US7772243B2 (en)
EP (1) EP1746999B1 (en)
JP (2) JP4205757B2 (en)
KR (2) KR20080095915A (en)
CN (1) CN1972688B (en)
AP (1) AP2204A (en)
AR (1) AR048652A1 (en)
AT (1) AT533490T (en)
AU (1) AU2005239878B9 (en)
BR (1) BRPI0510604A (en)
CA (1) CA2565812C (en)
CR (1) CR8727A (en)
CY (1) CY1112127T1 (en)
DK (1) DK1746999T3 (en)
EA (1) EA011237B1 (en)
EC (1) ECSP066976A (en)
ES (1) ES2374553T3 (en)
GE (1) GEP20084551B (en)
GT (1) GT200500103A (en)
HK (1) HK1106432A1 (en)
HN (1) HN2005000192A (en)
HR (1) HRP20110958T1 (en)
HU (1) HUS1900039I1 (en)
IL (1) IL178822A (en)
LT (1) LTPA2019016I1 (en)
MA (1) MA28632B1 (en)
ME (1) ME01267B (en)
MX (1) MXPA06012756A (en)
MY (1) MY143566A (en)
NI (1) NI200600262A (en)
NL (1) NL1028967C2 (en)
NO (2) NO339692B1 (en)
NZ (1) NZ550796A (en)
PA (1) PA8631901A1 (en)
PE (1) PE20060215A1 (en)
PL (1) PL1746999T3 (en)
PT (1) PT1746999E (en)
RS (1) RS52119B (en)
SI (1) SI1746999T1 (en)
TN (1) TNSN06360A1 (en)
TW (1) TWI334865B (en)
UA (1) UA85706C2 (en)
UY (1) UY28885A1 (en)
WO (1) WO2005107758A1 (en)
ZA (1) ZA200609012B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374553T3 (en) 2004-05-06 2012-02-17 Warner-Lambert Company Llc 4-phenylamine-quinazolin-6-il-amidas.
KR100735639B1 (en) 2004-12-29 2007-07-04 한미약품 주식회사 Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof
KR100929146B1 (en) 2006-06-28 2009-12-01 한미약품 주식회사 Quinazoline derivatives having the Cytotoxic Effects
CA2754808C (en) 2009-03-11 2019-01-08 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
CN102146059A (en) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 Quinazoline derivatives and preparation method and application thereof
CN102382065B (en) * 2010-08-30 2014-05-28 山东轩竹医药科技有限公司 Aniline substituted quinazoline derivative
CN102382106A (en) 2010-08-30 2012-03-21 黄振华 Aniline substituted quinazoline derivative
CN102452989B (en) * 2010-10-19 2014-10-22 山东轩竹医药科技有限公司 Aniline substituted quinazoline derivative
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
JP5859118B2 (en) * 2011-05-26 2016-02-10 山東軒竹医薬科技有限公司 Quinazoline derivatives as tyrosine kinase inhibitors, their preparation and use
CN102838590B (en) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs
WO2013053206A1 (en) * 2011-10-12 2013-04-18 Teligene Ltd Quinazoline derivatives as kinases inhibitors and methods of use thereof
TWI532727B (en) 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 Pyrazinecarboxamide compound
JP2015515995A (en) 2012-05-07 2015-06-04 テリジェン リミテッドTeligene Ltd Substituted aminoquinazolines useful as kinase inhibitors
TWI609012B (en) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 Aminoquinazoline derivatives and their salts and methods of use thereof
CN103288759B (en) * 2013-05-16 2015-05-20 苏州明锐医药科技有限公司 Method for preparing dacomitinib
CN103288758B (en) * 2013-05-16 2015-01-21 苏州明锐医药科技有限公司 Preparation method of dacomitinib (I)
WO2014187319A1 (en) 2013-05-21 2014-11-27 Jiangsu Medolution Ltd Substituted pyrazolopyrimidines as kinases inhibitors
CN103304492B (en) * 2013-06-20 2015-12-23 湖南欧亚生物有限公司 The synthetic method of a kind of EGFR inhibitor Dacomitinib
CN107892684A (en) * 2013-07-18 2018-04-10 锦州奥鸿药业有限责任公司 Quinazoline derivant and its pharmaceutical composition, and the purposes as medicine
CN105859641B (en) * 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 The crystal and its preparation method and application of quinazoline crotonyl compounds 2-maleate
WO2017117680A1 (en) * 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
CN107721985A (en) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 The crystal formation of quinazolines tyrosine kinase inhibitor
CN107721987A (en) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 The crystal formation of quinazolines tyrosine kinase inhibitor
CN107721986A (en) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 The crystal formation of quinazolines tyrosine kinase inhibitor

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
MX22406A (en) 1989-09-15 1994-01-31 Pfizer Novel N-aryl and n-heteroarylamides and urea as inhibitors of acyl coenzyme A: cholesterol acyltransferase of (ACAT).
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
CZ281628B6 (en) * 1991-07-29 1996-11-13 Warner-Lambert Company Quinazoline derivatives and pharmaceutical preparations based thereon and their use
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
WO1993004052A1 (en) 1991-08-22 1993-03-04 Warner-Lambert Company Amide tetrazole acat inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5412714A (en) * 1992-02-24 1995-05-02 At&T Corp. Mnemonic and synonymic addressing in a telecommunications system
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
NZ278135A (en) * 1994-02-23 1998-03-25 Pfizer Nitrogen containing heterocyclically substituted quinazoline derivatives and pharmaceutical compositions
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU5343096A (en) * 1995-04-27 1996-11-18 Zeneca Limited Quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE69633196D1 (en) * 1995-10-16 2004-09-23 Fujisawa Pharmaceutical Co Heterocyclic compounds as h + atpases
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
KR19990082463A (en) * 1996-02-13 1999-11-25 돈 리사 로얄 Quinazoline derivatives as inhibitors of vascular endothelial growth factor
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL125954A (en) * 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
PL190489B1 (en) 1996-04-12 2005-12-30 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69716916T2 (en) 1996-07-13 2003-07-03 Glaxo Group Ltd Condensed heterocyclic compounds as protein kinase inhibitors
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
AU743024B2 (en) 1997-03-05 2002-01-17 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
ZA9802771B (en) 1997-04-03 1999-10-01 American Cyanamid Co Substituted 3-Cyano Quinolines.
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc Quinazoline-based compound, famaceutica composition comprising it, to synthesize method, use, methods of modulating the function deserina / threonine protein kinase with said compound and in vitro method for identifying compounds that modulate said function
DK0980244T3 (en) 1997-05-06 2003-09-29 Wyeth Corp Use of quinazoline compounds to treat polycystic kidney disease
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ZA9806732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA9806729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
WO1999024037A1 (en) 1997-11-06 1999-05-20 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
HU0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
AT309225T (en) 1998-07-30 2005-11-15 Wyeth Corp Substituted chinazoline derivatives
ES2457396T3 (en) 1998-09-29 2014-04-25 Wyeth Holdings Llc 3-Substituted cyanoquinolines as protein tyrosine kinase inhibitors
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AT229008T (en) 1998-11-19 2002-12-15 Warner Lambert Co N- 4- (3-chloro-4-fluoro-phenylamino) -7- (3-morfolin-4-yl-propoxy) -quinazolin-6-yl -akrylamid, an irreversible tyrosine kinases inhibitor
PL351619A1 (en) 1999-02-27 2003-05-19 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
RS49836B (en) * 1999-03-31 2008-08-07 Pfizer Products Inc., Process and intermediates for preparing anti-cancer compounds
IL147133D0 (en) 1999-06-21 2002-08-14 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
AUPQ113799A0 (en) * 1999-06-22 1999-07-15 University Of Queensland, The A method and device for measuring lymphoedema
HU0203162A3 (en) 1999-08-12 2006-07-28 Wyeth Holdings Corp Madison Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
EE200200149A (en) 1999-09-21 2003-04-15 Astrazeneca Ab Quinazoline and pharmaceutical compositions containing them
US6664390B2 (en) * 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
SI1274692T1 (en) 2000-04-07 2006-12-31 Astrazeneca Ab Quinazoline compounds
MXPA02009855A (en) 2000-04-08 2003-03-27 Boehringer Ingelheim Pharma Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them.
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
IL152754D0 (en) 2000-06-06 2003-06-24 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
DE10031971A1 (en) * 2000-06-30 2002-01-10 Goedecke Ag Polymorphic forms / hydrates of N- [4- (3-chloro-4-fluoro-phenylamino) -7- (3-morpholin-4-yl-propoxy) -quinazolin-6-yl] -acrylamide dihydrochloride, processes for their preparation and to the use thereof for the preparation of medicaments with irreversible Tyrosinkinasehemmwirkung
US6446671B2 (en) * 2000-08-04 2002-09-10 John G. Armenia Double wall safety hose
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en) * 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE60126997T2 (en) * 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic ring compounds for the treatment of tumorary diseases
DE10063435A1 (en) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate medicaments containing these compounds, their use and processes for their preparation
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
PA8539401A1 (en) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolines as inhibitors of MMP-13
US7294629B2 (en) 2001-02-21 2007-11-13 Mitsubishi Pharma Corporation Quinazoline derivatives
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
GB0118752D0 (en) * 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CA2465068A1 (en) 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
BR0214606A (en) * 2001-11-30 2004-09-14 Pfizer Prod Inc Processes for the Preparation of Substituted Bicyclic Derivatives for the Treatment of Abnormal Cell Growth
KR20040063948A (en) * 2001-12-12 2004-07-14 화이자 프로덕츠 인크. Quinazoline Derivatives for the Treatment of Abnormal Cell Growth
CA2471577C (en) 2001-12-24 2011-08-02 Astrazeneca Ab Chemical compounds
DE10204462A1 (en) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
BR0307786A (en) 2002-02-26 2004-12-07 Astrazeneca Ab Pharmaceutical composition, method for preparing same, methods for inhibiting the rate of precipitation of the solution agent in the GI tract, and for reducing inter-patient variability with respect to bioavailability and / or plasma concentrations of the agent, and use of a water soluble ether cellulose or an ester of a water soluble ether cellulose
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10217689A1 (en) * 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10221018A1 (en) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US20040048887A1 (en) * 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
PA8578001A1 (en) 2002-08-07 2004-05-07 Warner Lambert Co Therapeutic combinations kinase inhibitors by antineoplastic therapies erb
EP1594504A4 (en) 2003-01-23 2008-12-17 T K Signal Ltd Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis
PE20040945A1 (en) * 2003-02-05 2004-12-14 Warner Lambert Co Preparation of substituted quinazolines
US7223749B2 (en) * 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2521348A1 (en) * 2003-04-09 2004-10-21 Pfizer Products Inc. Processes for the preparation of n-((((pyridinyloxy)-phenylamino) quinazolinyl)-allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
US7691867B2 (en) 2003-04-16 2010-04-06 Astrazeneca Ab Chemical compounds
KR20060037447A (en) 2003-08-18 2006-05-03 화이자 프로덕츠 인크. Dosing schedule for erbb2 anticancer agents
EP1673346A1 (en) 2003-10-06 2006-06-28 GPC Biotech AG Quinazoline derivatives for the treatment of herpesviral infections
CA2547284A1 (en) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation Quinazoline derivative and process for producing the same
ES2374553T3 (en) 2004-05-06 2012-02-17 Warner-Lambert Company Llc 4-phenylamine-quinazolin-6-il-amidas.

Also Published As

Publication number Publication date
TNSN06360A1 (en) 2008-02-22
AP2204A (en) 2011-02-07
IL178822D0 (en) 2007-03-08
TWI334865B (en) 2010-12-21
CN1972688B (en) 2012-06-27
NI200600262A (en) 2008-03-07
PT1746999E (en) 2012-01-11
NO339692B1 (en) 2017-01-23
KR20080095915A (en) 2008-10-29
KR20070008683A (en) 2007-01-17
NO20065626L (en) 2007-01-23
MXPA06012756A (en) 2007-01-16
CA2565812A1 (en) 2005-11-17
AU2005239878A1 (en) 2005-11-17
RS52119B (en) 2012-08-31
GT200500103A (en) 2006-01-10
AT533490T (en) 2011-12-15
US8623883B2 (en) 2014-01-07
EA200601849A1 (en) 2007-04-27
US20130274275A1 (en) 2013-10-17
CN1972688A (en) 2007-05-30
ECSP066976A (en) 2006-12-29
UA85706C2 (en) 2009-02-25
PL1746999T3 (en) 2012-07-31
GEP20084551B (en) 2008-11-25
US20050250761A1 (en) 2005-11-10
AU2005239878B2 (en) 2009-09-03
JP4966923B2 (en) 2012-07-04
US7772243B2 (en) 2010-08-10
US8466165B2 (en) 2013-06-18
BRPI0510604A (en) 2007-10-30
NL1028967A1 (en) 2005-11-08
US20100190977A1 (en) 2010-07-29
EP1746999B1 (en) 2011-11-16
MY143566A (en) 2011-05-31
TW200540163A (en) 2005-12-16
PE20060215A1 (en) 2006-03-20
DK1746999T3 (en) 2012-01-23
ME01267B (en) 2013-06-20
HUS1900039I1 (en) 2019-10-28
JP2009007363A (en) 2009-01-15
NZ550796A (en) 2010-07-30
PA8631901A1 (en) 2005-11-25
EP1746999A1 (en) 2007-01-31
ZA200609012B (en) 2008-06-25
IL178822A (en) 2013-07-31
JP2007536368A (en) 2007-12-13
CR8727A (en) 2006-11-30
CY1112127T1 (en) 2015-11-04
UY28885A1 (en) 2005-12-30
AU2005239878B9 (en) 2010-01-07
WO2005107758A1 (en) 2005-11-17
NL1028967C2 (en) 2006-06-27
HK1106432A1 (en) 2012-12-28
LTPA2019016I1 (en) 2019-09-25
KR100885835B1 (en) 2009-02-26
AR048652A1 (en) 2006-05-10
JP4205757B2 (en) 2009-01-07
EA011237B1 (en) 2009-02-27
ES2374553T3 (en) 2012-02-17
NO2019035I1 (en) 2019-09-13
HN2005000192A (en) 2010-06-09
CA2565812C (en) 2012-03-13
MA28632B1 (en) 2007-06-01
SI1746999T1 (en) 2012-01-31
HRP20110958T1 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
TWI346544B (en) Knochenschraube
ZA200609595B (en) Novel CIS-Imidazolines
DE602005026498D1 (en) R prothese
IL241732A (en) 2-di-tert-butyloxycarbonylamino-6-bromo-9-(2-trimehylsilylethoxy)methyl-9h-purine
GB0426736D0 (en) MyFone
DE602005003960D1 (en) Oximesther-fotoinitiatoren
SI1802198T1 (en) Synergistische fungizide Zusammensetzungen
DE602005017576D1 (en) Wirbel-osteosynthese-gerät
DE602005025924D1 (en) Royl-coa-desaturase
EP1769743A4 (en) Radiotomograph
DE602005022165D1 (en) Fluidleitungsverbindervorrichtung
DE602005003667D1 (en) Sandwich-hybridmontagematte
DE602005025220D1 (en) Thernet-kabel
DE602005020252D1 (en) Röhrenförmige prothese
IL179730D0 (en) Novel cis-imidazolines
DE502005007844D1 (en) Phasenstabile polyurethanprepolymere
TWI346750B (en) Planetenradgetriebe
EP1790612A4 (en) Nanocapsule-type structure
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
PL1593299T3 (en) Rotobaler
EP1793751A4 (en) Compressor-distractor
IL182983D0 (en) 4-hydroxybenzomorphans
DE602005010905D1 (en) Roboterhandvorrichtung
DE602005018033D1 (en) Luftreinigungsvorrichtung
DE602005027562D1 (en) Aliphatisches polyestercopolymer